Bafna Pharmaceuticals Ltd vs Wockhardt Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 135.7 as of 30 Apr 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Wockhardt Ltd changed from 6.7 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Wockhardt Ltd changed from ₹ 4590 crore on March 2021 to ₹ 23133 crore on March 2025 . This represents a CAGR of 38.19% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Wockhardt Ltd for the Dec '25 is ₹ 913 crore as compare to the Sep '25 revenue of ₹ 803 crore. This represent the growth of 13.7% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Wockhardt Ltd for the Dec '25 is ₹ 192 crore as compare to the Sep '25 ebitda of ₹ 199 crore. This represent the decline of -3.52% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Wockhardt Ltd changed from ₹ -16 crore to ₹ 61 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Wockhardt Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Wockhardt Ltd

Wockhardt Limited, incorporated in July, 1999 is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world.
The Company is India's leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out. The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland.
It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses.
Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Wockhardt Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Wockhardt Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 321 Cr while Market cap of Wockhardt Ltd is 22,661 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Wockhardt Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Wockhardt Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Wockhardt Ltd?

As of May 3, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹135.7. On the other hand, Wockhardt Ltd stock price is INR ₹1394.6.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Wockhardt Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Wockhardt Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.